Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add filters








Language
Year range
1.
Chinese Journal of Biochemical Pharmaceutics ; (6): 156-157,160, 2017.
Article in Chinese | WPRIM | ID: wpr-659965

ABSTRACT

Objective To observe the effect of montelukast combined with budesonide on FEV1%, symptom score and adverse reaction in moderate to severe bronchial asthma patients. Methods 70 patients with moderate to severe bronchial asthma from April 2016 to April 2017 were randomly divided into single group and combined group. 35 patients in a single group were treated with budesonide, combined group 35 patients were treated with montelukast combined with budesonide, and the therapeutic effects were compared between the two groups after treatment. Results There were no differences in the scores of lung function and symptoms between two groups before treatment, and there was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the lung function index, symptom score and total effective treatment of the combined group were obvious better than that of the single group (P<0.05). Conclusion Montelukast combined with budesonide in the treatment of moderate to severe bronchial asthma has good effect and high safety. It reduces the number of asthma attacks and improves the lung function of patients. It is worthy to be widely used and widely used in clinical practice.

2.
Chinese Journal of Biochemical Pharmaceutics ; (6): 156-157,160, 2017.
Article in Chinese | WPRIM | ID: wpr-657660

ABSTRACT

Objective To observe the effect of montelukast combined with budesonide on FEV1%, symptom score and adverse reaction in moderate to severe bronchial asthma patients. Methods 70 patients with moderate to severe bronchial asthma from April 2016 to April 2017 were randomly divided into single group and combined group. 35 patients in a single group were treated with budesonide, combined group 35 patients were treated with montelukast combined with budesonide, and the therapeutic effects were compared between the two groups after treatment. Results There were no differences in the scores of lung function and symptoms between two groups before treatment, and there was no significant difference in the incidence of adverse reactions between the two groups. After treatment, the lung function index, symptom score and total effective treatment of the combined group were obvious better than that of the single group (P<0.05). Conclusion Montelukast combined with budesonide in the treatment of moderate to severe bronchial asthma has good effect and high safety. It reduces the number of asthma attacks and improves the lung function of patients. It is worthy to be widely used and widely used in clinical practice.

SELECTION OF CITATIONS
SEARCH DETAIL